Merck & Co., Inc. (MRK) Tops Q2 EPS by 5c
Get Alerts MRK Hot Sheet
EPS Growth %: +46.4%
Financial Fact:
Income Before Taxes: 10.82B
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
(Updated - July 29, 2014 6:59 AM EDT)
Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $10.93 billion versus the consensus estimate of $10.6 billion.
“We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs, while focusing on our best opportunities,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I’m excited as we are preparing for a series of important and promising product launches later this year that we believe will make a meaningful difference to patients, healthcare providers and payers, while creating value for society and shareholders.”
The following table reflects sales of the company's top pharmaceutical products, as well as total sales of Animal Health and Consumer Care products.
Second Quarter | Second Quarter | Change | Change | ||||||||
$ in millions | 2014 | 2013 | Ex-exchange | ||||||||
Total Sales | $10,934 | $11,010 | -1% | -1% | |||||||
Pharmaceutical | 9,087 | 9,310 | -2% | -2% | |||||||
JANUVIA/JANUMET | 1,577 | 1,547 | 2% | 2% | |||||||
ZETIA/VYTORIN | 1,134 | 1,067 | 6% | 5% | |||||||
REMICADE | 607 | 527 | 15% | 9% | |||||||
ISENTRESS | 453 | 412 | 10% | 10% | |||||||
GARDASIL | 409 | 383 | 7% | 9% | |||||||
PROQUAD, M-M-R II and VARIVAX | 326 | 339 | -4% | -3% | |||||||
SINGULAIR | 284 | 281 | 1% | 3% | |||||||
NASONEX | 258 | 325 | -21% | -20% | |||||||
Animal Health | 872 | 851 | 2% | 3% | |||||||
Consumer Care | 583 | 490 | 19% | 20% | |||||||
Other Revenues | 392 | 359 | 9% | 6% |
*** Outlook:
The company sees FY14 adjusted EPS of $3.43 - $3.53, versus consensus expectations of $3.48.
In addition, the company continues to expect full-year 2014 non-GAAP marketing and administrative as well as R&D expenses to be below 2013 levels. The company continues to anticipate its full-year 2014 non-GAAP tax rate to be in the range of 24 to 26 percent; the rate does not include a 2014 benefit of an R&D tax credit.
For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Red Cat Holdings Inc. (RCAT) Misses Q3 EPS by 5c
- Alpine Immune Sciences (ALPN) Reports FY Loss of $0.64
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!